Raymond James Financial Inc. Takes Position in Schrödinger, Inc. (NASDAQ:SDGR)

Raymond James Financial Inc. bought a new stake in shares of Schrödinger, Inc. (NASDAQ:SDGR - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 16,866 shares of the company's stock, valued at approximately $325,000.

Other hedge funds have also recently bought and sold shares of the company. Paradigm Asset Management Co. LLC bought a new position in shares of Schrödinger during the 4th quarter valued at about $50,000. GAMMA Investing LLC lifted its stake in Schrödinger by 87.5% during the fourth quarter. GAMMA Investing LLC now owns 2,796 shares of the company's stock valued at $54,000 after purchasing an additional 1,305 shares during the last quarter. Quarry LP boosted its holdings in Schrödinger by 1,150.0% during the third quarter. Quarry LP now owns 2,825 shares of the company's stock worth $52,000 after buying an additional 2,599 shares in the last quarter. KBC Group NV grew its position in Schrödinger by 73.9% in the fourth quarter. KBC Group NV now owns 4,361 shares of the company's stock worth $84,000 after buying an additional 1,853 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new position in shares of Schrödinger in the fourth quarter valued at $218,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Schrödinger Trading Down 3.9 %

NASDAQ SDGR traded down $1.04 during trading on Tuesday, reaching $25.50. 692,291 shares of the company's stock were exchanged, compared to its average volume of 804,998. Schrödinger, Inc. has a fifty-two week low of $16.60 and a fifty-two week high of $28.47. The company's fifty day simple moving average is $21.99 and its 200-day simple moving average is $20.81. The firm has a market capitalization of $1.86 billion, a PE ratio of -10.84 and a beta of 1.77.

Remove Ads

Schrödinger (NASDAQ:SDGR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The firm had revenue of $88.32 million for the quarter, compared to analysts' expectations of $83.20 million. Equities analysts forecast that Schrödinger, Inc. will post -2.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SDGR has been the topic of a number of recent analyst reports. Piper Sandler cut their target price on Schrödinger from $50.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, February 27th. KeyCorp boosted their price objective on Schrödinger from $25.00 to $27.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Schrödinger presently has an average rating of "Buy" and an average price target of $32.29.

Insider Activity at Schrödinger

In other Schrödinger news, CFO Geoffrey Craig Porges sold 5,491 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $21.76, for a total transaction of $119,484.16. Following the transaction, the chief financial officer now directly owns 27,544 shares of the company's stock, valued at $599,357.44. This represents a 16.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 8.60% of the stock is currently owned by company insiders.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.